No Data
No Data
Wei Xinkang (603676.SH): Some directors and senior management plan to reduce their share holdings
Ge Longhui, May 21丨Wei Xinkang (603676.SH) announced that due to personal capital requirements, Mr. Liu Feng plans to reduce the number of company shares held by no more than 954,280 shares through centralized bidding on the Shanghai Stock Exchange within 3 months after 15 trading days from the date of disclosure of this announcement, with a reduction ratio of no more than 0.22% of the company's total shares; due to personal capital requirements, Ms. Liu Binbin plans to reduce the company's holdings through centralized bidding on the Shanghai Stock Exchange within 3 months after 15 trading days from the disclosure of this announcement The number of shares shall not exceed 221,
Wei Xinkang (603676.SH): Does not involve synthetic biotechnology
Gelonghui, May 9丨Wei Xinkang (603676.SH) said on the investor interactive platform that the company's main business is R&D, production, and sales of chemical preparations and their APIs, and is currently not involved in synthetic biotechnology.
Weixinkang (603676.SH) subsidiary obtained drug registration certificate for potassium aspartate injection
Zhitong Finance App News, Wei Xinkang (603676.SH) issued an announcement. Recently, Yangpu Jingtai Pharmaceutical Co., Ltd. (“Yangpu Jingtai”), a wholly-owned subsidiary of the company, received the “Drug Registration Certificate” for potassium aspartate injections approved and issued by the State Drug Administration. Potassium aspartate injection is an electrolyte supplement. It is used for hypokalemia caused by various causes. This product can be used to supplement potassium when the following symptoms or conditions occur: when combined with antihypertensive diuretics, adrenocortical hormones, cardiac glycosides, insulin, or certain antibiotics; low-potassium periodic limb paralysis; hypokalemia in the case of heart disease
Wei Xinkang (603676.SH) announced first-quarter results, net profit of 94.914,700 yuan, an increase of 57.54% year-on-year
Wei Xinkang (603676.SH) released its report for the first quarter of 2024. During the reporting period, the company achieved operating income of 3...
Wei Xinkang (603676.SH): Received 41.8641 million yuan in government grants
Gelonghui, March 29丨Wei Xinkang (603676.SH) announced that Tibet Zhongwei Chengkang Pharmaceutical Co., Ltd., a wholly-owned subsidiary of the company, received 418.64,100 yuan in government subsidies related to revenue, accounting for 23.66% of the company's 2022 audited net profit attributable to shareholders of listed companies.
[Instant Analysis of BT Financial Report] Wei Xinkang 2023 Third Quarter Report: Net profit increased significantly, balance ratio declined, and net operating cash flow decreased
Announcement time of this financial report: 2023-10-24 16:07:53 Wei Xinkang (stock code: 603676) is a comprehensive pharmaceutical enterprise, mainly engaged in pharmaceutical R&D, production and sales. According to earnings data for the third quarter of 2023, there are some notable changes in the company's operating conditions and financial performance. First, in terms of assets and liabilities, Wei Xinkang's total assets reached 1,772 billion yuan at the end of this reporting period, up from 1,665 billion yuan at the end of the previous year. Total liabilities at the end of this reporting period were $428 million, compared to 444 million yuan at the end of the previous year
No Data